Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Collegium PharmaceuticalCOLL -7.16%79 EV-to-EBIT is 12.03 as of Aug. 10, 2026, which is 40% above its 10-year median of 8.60. GuruFocus rates COLL with a GF Score™ of 79/100 and a GF Value™ of $46.67 (Possible Value Trap). The stock has 3 warning signs investors should review. Among 683 Drug Manufacturers companies, Collegium Pharmaceutical ranks better than 60.32% on this metric.
Collegium Pharmaceutical (NAS:COLL) EV-to-EBIT Explanation
This is a more accurate valuation of companies' operation because it considers the debt and cash on its balance sheet, and non-operating items such as interest payment, tax, and one-time items are not included in the Operating Income.
Collegium Pharmaceutical's Enterprise Value for the quarter that ended in Jun. 2026 was $2,142.1 Mil.
Collegium Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $154.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical EV-to-EBIT Related Terms
Collegium Pharmaceutical EV-to-EBIT Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Drug Manufacturers - Specialty & Generic subindustry, Collegium Pharmaceutical's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Collegium Pharmaceutical EV-to-EBIT vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Collegium Pharmaceutical's EV-to-EBIT distribution charts can be found below:
* The bar in red indicates where Collegium Pharmaceutical's EV-to-EBIT falls into.
Collegium Pharmaceutical's current Enterprise Value is $1,854.4 Mil.
Collegium Pharmaceutical's EBIT for the trailing twelve months (TTM) ended in Jun. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $154.1 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Collegium Pharmaceutical (COLL) has a EV-to-EBIT of 12.03 as of Aug. 10, 2026. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Collegium Pharmaceutical and its competitors. This is 40% above median its historical median of 8.60. According to the industry distribution chart, Collegium Pharmaceutical ranks #271 out of 683 companies in the Drug Manufacturers industry, placing it in the top 39.7%.
Is Collegium Pharmaceutical's EV-to-EBIT too high?
Collegium Pharmaceutical's current EV-to-EBIT of 12.03 is 40% above median its 10-year median of 8.60. The Drug Manufacturers industry median EV-to-EBIT is 15.66. Collegium Pharmaceutical's value of 12.03 is 23.2% below this industry median. Based on the distribution chart, Collegium Pharmaceutical ranks #271 out of 683 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Collegium Pharmaceutical has a GF Score™ of 79/100 and is considered Possible Value Trap, reflecting its overall financial health beyond just this single metric.
How does Collegium Pharmaceutical's EV-to-EBIT compare to ETON and ALVO?
According to the Drug Manufacturers industry distribution chart, Collegium Pharmaceutical ranks #271 out of 683 companies for EV-to-EBIT. This puts Collegium Pharmaceutical in the upper half of its industry. The industry median EV-to-EBIT is 15.66. Collegium Pharmaceutical's value of 12.03 is 23.2% below this benchmark. While the company's 10-year median is 8.60 vs. the industry median of 15.66, Collegium Pharmaceutical has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EV-to-EBIT for a Drug Manufacturers company?
The median EV-to-EBIT among Drug Manufacturers companies is 15.66, based on 683 companies in the industry. Companies in the top quartile (top 25%) have a EV-to-EBIT significantly above this median, while those in the bottom quartile fall well below. However, EV-to-EBIT should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Collegium Pharmaceutical's current EV-to-EBIT of 12.03 is 23.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EV-to-EBIT mean?
A high EV-to-EBIT can signal that a stock is expensive relative to its fundamentals. EV to EBIT ratio is the inverse of Joel Greenblatt's earnings yield definition. View historical data on Collegium Pharmaceutical and its competitors. For the Drug Manufacturers industry, the median EV-to-EBIT is 15.66 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Collegium Pharmaceutical's current EV-to-EBIT is 12.03, which is 40% above median its own 10-year median of 8.60. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Collegium Pharmaceutical stock overvalued right now?
Based on GuruFocus' analysis, Collegium Pharmaceutical (COLL) is currently considered Possible Value Trap. The stock's GF Value™ is $46.67, compared to a current price of $27.36 — trading 41.4% below its estimated fair value. The current EV-to-EBIT is 12.03, which is 40% above median its 10-year median of 8.60 and 23.2% below the Drug Manufacturers industry median of 15.66. Collegium Pharmaceutical's overall GF Score™ is 79/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EV-to-EBIT calculated?
EV-to-EBIT is calculated from a company's financial statements. For Collegium Pharmaceutical (COLL), the current EV-to-EBIT is 12.03 as of Aug. 10, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Collegium Pharmaceutical (COLL) Overvalued in 2026?
Based on GuruFocus' analysis, Collegium Pharmaceutical stock appears to be undervalued.
The current stock price of $27.36 is trading 41.4% below its estimated GF Value™ of $46.67.
GuruFocus considers Collegium Pharmaceutical to be Possible Value Trap.
Key valuation signals for COLL:
EV-to-EBIT: 12.03 (40% above median its 10-year median of 8.60)
GF Value™: $46.67 vs. price of $27.36 (41.4% below fair value)
Industry Position: 23.2% below the Drug Manufacturers median (#271 of 683)
No single metric tells the full story. See the COLL stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Collegium Pharmaceutical Inc is a diversified biopharmaceutical company committed to improving the lives of people living with serious medical conditions. The company has developed, licensed, and acquired a portfolio of meaningfully differentiated products for the treatment of attention deficit hyperactivity disorder (ADHD) and moderate to severe pain. It commercializes its products in the United States, including Jornay PM, Belbuca, Xtampza ER, Nucynta ER, Nucynta IR (collectively, the Nucynta Products), and Symproic. The company's product portfolio includes Jornay PM, Belbuca, Xtampza ER, Nucynta IR, Nucynta ER, and Symproic.
79GF Score
Get the complete analysis for COLL
EV-to-EBIT is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
COLL has been successfully added to your 
